Volume 16, Issue 2 (2009)
Introduction
Articles
The Regulation of Nanomedicine: Will the Existing Regulatory Scheme of the FDA Suffice?
Shanna Harris
Will The Federal Circuit’s Eli Lilly V. Teva Decision Lead To Efforts To Abuse The Modification Provision Of The Hatch-Waxman Act?
Claire K. Comfort